Agios Pharmaceuticals
AGIO
144 hedge funds and large institutions have $2.14B invested in Agios Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 42 reducing their positions, and 25 closing their positions.
101% more call options, than puts
Call options by funds: $20.6M | Put options by funds: $10.2M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 42
3% less capital invested
Capital invested by funds: $2.21B → $2.14B (-$71.9M)
4% less funds holding
Funds holding: 150 → 144 (-6)
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
Top Buyers
| 1 |
ClearBridge Investments
New York
|
+$65.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$19M |
| 4 |
Jennison Associates
New York
|
+$17.8M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$8.16M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$20.7M |
| 2 |
CC
Cannell & Co
New York
|
-$11.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$10.5M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$7.73M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
-$7.15M |
AGIO Hedge Fund Activity: Q4 2015 in Review
144 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2015, worth a combined $2.14B — down 3.2% from $2.21B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of AGIO and 20 opened new positions — a net loss of 5 holders — while 42 trimmed existing stakes and 58 added.
The largest buyer was ClearBridge Investments, adding an estimated $65.6M. The largest seller was AllianceBernstein, cutting an estimated $20.7M.
- 144 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2015, down from 150 in Q3 2015.
- Funds reported $2.14B of Agios Pharmaceuticals stock for Q4 2015, down 3.2% quarter-over-quarter.
- 20 funds opened new Agios Pharmaceuticals positions in Q4 2015 and 25 closed out, a net change of -5 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2015 was ClearBridge Investments, an estimated $65.6M added.
- The largest Agios Pharmaceuticals seller in Q4 2015 was AllianceBernstein, an estimated $20.7M sold.
Based on aggregated 13F filings for Q4 2015.